Arecor Therapeutics plc (AIM:AREC)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 36.24M +34.2% |
| Revenue (ttm) | 890.00K -22.9% |
| Net Income | 190.00K |
| EPS | 0.01 |
| Shares Out | 45.30M |
| PE Ratio | 158.98 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,703 |
| Open | 80.00 |
| Previous Close | 82.50 |
| Day's Range | 80.00 - 80.00 |
| 52-Week Range | 55.27 - 95.00 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 250.50 (+213.13%) |
| Earnings Date | Oct 12, 2026 |
About Arecor Therapeutics
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company’s lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AREC stock is "Strong Buy." The 12-month stock price target is 251p, which is an increase of 213.13% from the latest price.
News
Arecor Therapeutics Quarterly report: H1 2026
Arecor Therapeutics has published its H1 2026 quarterly earnings report on September 30, 2026.
Arecor Therapeutics Slides: Investor presentation
Arecor Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Arecor Therapeutics Earnings Call Transcript: H2 2025
Revenue and cash position improved, supported by a $11M non-dilutive financing and reduced expenses. AT278 insulin and oral peptide delivery platforms advance, with phase II trials and key data expected in 2026. Strategic partnerships and a strong cash runway support growth.
Arecor Therapeutics Annual report: H2 2025
Arecor Therapeutics has published its H2 2025 annual report on April 23, 2026.
Arecor Therapeutics Slides: H2 2025
Arecor Therapeutics has posted slides in relation to its H2 2025 quarterly earnings report, which was published on April 23, 2026.
Arecor Therapeutics Annual report: H2 2025
Arecor Therapeutics has published its H2 2025 annual report on April 23, 2026.
Arecor Therapeutics Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
AT278, an ultra-concentrated, ultra-rapid insulin, targets unmet needs in AID systems, with phase II trials planned and a $3–5 billion U.S. market opportunity. The company is also advancing an oral peptide delivery platform, aiming to improve GLP-1 bioavailability and expand partnerships.
Arecor Therapeutics Slides: Investor presentation
Arecor Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
AIM Market Roundup: Wishbone, Nativo Resources, Arecor Therapeutics
Wishbone, Nativo Resources, Arecor Therapeutics, Proteome Sciences and Bradda Head Lithium are today's top movers on London's AIM market
Arecor extends cash runway with US partnerships
Arecor has bolstered its balance sheet and sharpened its clinical focus, signing two US partnerships that will accelerate its drug pipeline.
AIM Market Roundup: The Revel Collective, Tanfield, Arecor
The Revel Collective, Tanfield, Arecor are today's top risers, while Pantheon Resources, Acuity RM take the biggest fall on London's AIM